Shu Hongyang, Peng Yizhong, Hang Weijian, Zhou Ning, Wang Dao Wen
Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hubei Key Laboratory of Genetics and Molecular Mechanism of Cardiologic Disorders, Huazhong University of Science and Technology, Wuhan, China.
Front Pharmacol. 2021 Jan 12;11:569132. doi: 10.3389/fphar.2020.569132. eCollection 2020.
Heart failure is a systemic syndrome caused by multiple pathological factors. Current treatments do not have satisfactory outcomes. Several basic studies have revealed the protective effect of trimetazidine on the heart, not only by metabolism modulation but also by relieving myocardial apoptosis, fibrosis, autophagy, and inflammation. Clinical studies have consistently indicated that trimetazidine acts as an adjunct to conventional treatments and improves the symptoms of heart failure. This review summarizes the basic pathological changes in the myocardium, with an emphasis on the alteration of cardiac metabolism in the development of heart failure. The clinical application of trimetazidine in heart failure and the mechanism of its protective effects on the myocardium are carefully discussed, as well as its main adverse effects. The intention of this review is to highlight this treatment as an effective alternative against heart failure and provide additional perspectives for future studies.
心力衰竭是一种由多种病理因素引起的全身性综合征。目前的治疗效果并不理想。几项基础研究已经揭示了曲美他嗪对心脏的保护作用，不仅通过调节代谢，还通过减轻心肌细胞凋亡、纤维化、自噬和炎症。临床研究一致表明，曲美他嗪可作为传统治疗的辅助药物，改善心力衰竭症状。本综述总结了心肌的基本病理变化，重点是心力衰竭发展过程中心脏代谢的改变。仔细讨论了曲美他嗪在心力衰竭中的临床应用及其对心肌的保护作用机制，以及其主要不良反应。本综述的目的是强调这种治疗方法是对抗心力衰竭的有效替代方案，并为未来的研究提供更多视角。
